These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25348580)

  • 1. Pegylated interferon therapy of chronic hepatitis D: in need of revision.
    Rizzetto M; Smedile A
    Hepatology; 2015 Apr; 61(4):1109-11. PubMed ID: 25348580
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.
    Ouzan D; Pénaranda G; Joly H; Halfon P
    J Hepatol; 2013 Jun; 58(6):1258-9. PubMed ID: 23318602
    [No Abstract]   [Full Text] [Related]  

  • 3. Current management of delta hepatitis.
    Rizzetto M
    Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a.
    Ferenci P; Formann E; Romeo R
    Am J Gastroenterol; 2005 Jul; 100(7):1626-7. PubMed ID: 15985000
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of pegylated interferon alpha-2b for the treatment of chronic delta hepatitis in a patient co-infected with HIV.
    Rosa I; Costes L; Garrait V; Chousterman M
    AIDS; 2005 Dec; 19(18):2177-8. PubMed ID: 16284472
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa.
    Maraolo AE; Minervini F; Tosone G
    Aliment Pharmacol Ther; 2015 Mar; 41(6):595. PubMed ID: 25659214
    [No Abstract]   [Full Text] [Related]  

  • 7. Can We Predict Sustained Virologic Response to Interferon α Therapy in Patients With Chronic Hepatitis Delta Virus Infection?
    Scholtès C; Kumar R; Zoulim F
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2350-2. PubMed ID: 26254201
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa--authors' reply.
    Koh C; Heller T
    Aliment Pharmacol Ther; 2015 Mar; 41(6):595-6. PubMed ID: 25659215
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
    Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
    Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis: antiviral treatment for hepatitis D.
    Triantos C; Kalafateli M; Nikolopoulou V; Burroughs A
    Aliment Pharmacol Ther; 2012 Mar; 35(6):663-73. PubMed ID: 22273482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
    Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
    Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of delta hepatitis.
    Gunsar F
    Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High dose of pegylated interferon alpha-2a for the treatment of genotype1 chronic hepatitis C: a case report].
    Wu CH; Wang LF; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):873. PubMed ID: 21138646
    [No Abstract]   [Full Text] [Related]  

  • 14. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months.
    Ormeci N; Bölükbaş F; Erden E; Coban S; Ekiz F; Erdem H; Palabıyıkoğlu M; Beyler AR; Balık I; Bölükbaş C; Nazlıgül Y; Köklü S
    Hepatogastroenterology; 2011; 58(110-111):1648-53. PubMed ID: 22086695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):246-8. PubMed ID: 24366456
    [No Abstract]   [Full Text] [Related]  

  • 16. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience.
    Abbas Z; Memon MS; Mithani H; Jafri W; Hamid S
    Antivir Ther; 2014; 19(5):463-8. PubMed ID: 24423484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBV/HDV Coinfection: A Challenge for Therapeutics.
    Koh C; Da BL; Glenn JS
    Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pegylated interferon: new progress in treatment for chronic hepatitis C].
    Boyer N; Marcellin P
    Gastroenterol Clin Biol; 2000; 24(8-9):767-9. PubMed ID: 11011255
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interferon therapy for chronic hepatitis B].
    Hige S; Sho T; Nakanishi M; Chuma M
    Nihon Rinsho; 2011 May; 69 Suppl 4():481-5. PubMed ID: 22096965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.